Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies-Reference-Cited by-同舟云学术

Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies

Published:2023-09 Issue: Volume: Page:
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Chan Kai En,Ong Elden Yen Hng,Chung Charlotte Hui,Ong Christen En Ya,Koh Benjamin,Tan Darren Jun Hao,Lim Wen Hui,Yong Jie Ning,Xiao Jieling,Wong Zhen Yu,Syn Nicholas,Kaewdech Apichat,Teng Margaret,Wang Jiong-Wei,Chew Nicholas,Young Dan Yock,Know Alfred,Siddiqui Mohammad Shadab,Huang Daniel Q.,Tamaki Nobuharu,Wong Vincent Wai-Sun,Mantzoros Christos S.,Sanyal Arun,Noureddin Mazen,Ng Cheng Han^ORCID,Muthiah Mark

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference178 articles.

1. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis;Quek;Lancet Gastroenterol Hepatol,2023

2. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis;Tan;Lancet Oncol,2022

3. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma;Noureddin;Clin Liver Dis,2015

4. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies;Kadayifci;J Hepatol,2008

5. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis;Cho;Gut,2023

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

2. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease;Nature Medicine;2024-09-03

3. Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD;Liver International;2024-09-02

4. Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly;Digestive and Liver Disease;2024-09

5. Risk Factors and Diagnostic Markers for Fatty Liver and Metabolic Syndrome Among Young Adults: Insights from a Community-Based Investigation;2024-08-09